Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis

Table 1

Patient characteristics.

Parameters		At diagnosis	At first event
Age	Median (range), years	44.5 (29–79)	52.0 (30–80)
	≤60	60 (86%)	55 (79%)
	>60	10 (14%)	15 (21%)
ECOG performance status	0/1	65 (93%)	65 (93%)
	≥2	5 (7%)	5 (7%)
Ann Arbor stage	I/II	7 (10%)	6 (9%)
	III/IV	63 (90%)	64 (91%)
FLIPI	Low risk (0–1)	19 (27%)	0 (0%)
	Intermediate risk (2)	26 (37%)	17 (24%)
	High risk (3–5)	25 (36%)	53 (76%)
Histologic grade	1	41 (59%)	33 (47%)
	2	16 (23%)	11 (16%)
	3A	13 (18%)	17 (24%)
	Large cell transformation	—	9 (13%)
Number of nodal involvements	≥5	36 (51%)	42 (60%)
	<5	34 (49%)	28 (40%)
Bone marrow involvement	Presence	43 (61%)	Unknown
B-symptoms	Presence	4 (6%)	3 (4%)
Elevated LDH	Presence	19 (27%)	67 (96%)
Treatment	RCVP	35 (50%)	—
	RCHOP	28 (40%)	7 (10%)
	BR	7 (10%)	17 (24%)
	Anti-CD20 antibody monotherapy	—	7 (10%)
	ICED/ESHAP	—	18 (26%)
	FND	—	12 (17%)
	Other treatments	—	6 (9%)
	Not applicable	—	3 (4%)

ECOG: eastern cooperative oncology group; FLIPI: follicular lymphoma international prognostic index; LDH: lactate dehydrogenase; RCVP: rituximab, cyclophosphamide, vincristine, and prednisone; RCHOP: rituximab, cyclophosphamide, vincristine, prednisone, and doxorubicin; BR: bendamustine and rituximab; ICED: ifosfamide, carboplatin, etoposide, and dexamethasone; ESHAP: etoposide, cisplatin, cytarabine, and methylprednisolone; FND: fludarabine, mitoxantrone, and dexamethasone.